Becton, Dickinson and Company $BDX Shares Bought by Graybill Wealth Management LTD.

Graybill Wealth Management LTD. lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 47.3% in the third quarter, Holdings Channel reports. The institutional investor owned 27,592 shares of the medical instruments supplier’s stock after buying an additional 8,859 shares during the quarter. Becton, Dickinson and Company accounts for approximately 1.6% of Graybill Wealth Management LTD.’s portfolio, making the stock its 27th biggest position. Graybill Wealth Management LTD.’s holdings in Becton, Dickinson and Company were worth $5,164,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in BDX. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares in the last quarter. Empowered Funds LLC raised its stake in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares in the last quarter. United Bank lifted its position in shares of Becton, Dickinson and Company by 23.9% during the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after purchasing an additional 993 shares during the last quarter. Creative Planning grew its stake in Becton, Dickinson and Company by 11.5% in the second quarter. Creative Planning now owns 55,463 shares of the medical instruments supplier’s stock worth $9,554,000 after purchasing an additional 5,736 shares in the last quarter. Finally, Cetera Investment Advisers grew its stake in Becton, Dickinson and Company by 6.0% in the second quarter. Cetera Investment Advisers now owns 83,538 shares of the medical instruments supplier’s stock worth $14,389,000 after purchasing an additional 4,700 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BDX. Barclays started coverage on Becton, Dickinson and Company in a research note on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada set a $172.00 price objective on Becton, Dickinson and Company in a research note on Tuesday, February 10th. Finally, Citigroup decreased their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $195.46.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $161.64 on Wednesday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a market capitalization of $46.03 billion, a price-to-earnings ratio of 26.37, a PEG ratio of 11.62 and a beta of 0.24. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The stock’s fifty day moving average is $188.36 and its two-hundred day moving average is $189.53.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same quarter in the prior year, the firm earned $3.43 earnings per share. The company’s quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be given a $1.05 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.6%. Becton, Dickinson and Company’s dividend payout ratio is 68.52%.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,787 shares of company stock worth $551,391 in the last 90 days. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.